Entero Healthcare Shares Surge 33% in One Week, Reach New Peak

Entero Healthcare Solutions experienced a notable rise in its share price, climbing 4 percent to reach ₹2,095.30 during intraday trading on Monday at the Bombay Stock Exchange (BSE). This marked a new high for the pharmacy retail company, which stood out in an otherwise stable market environment. The stock rebounded sharply, recovering 7 percent from a low of ₹1,967 earlier in the trading session. Over the past week, Entero Healthcare’s shares surged 33 percent, more than doubling from its 52-week low of ₹944 recorded on December 29, 2025.

By 2:51 PM, the share price was trading 3 percent higher at ₹2,090, outpacing the modest 0.11 percent increase in the BSE Sensex. This movement reflects growing investor confidence in Entero’s ongoing performance and prospects.

The company’s strong quarterly results for Q2 FY27 (July to September 2026) played a key role in driving the stock upward. Entero Healthcare posted a 33 percent year-on-year revenue jump to ₹2,087 crore, alongside a 5.3 percent EBITDA margin. Profit after tax saw an even more impressive rise, increasing 66 percent year-on-year to ₹60.70 crore. These figures underscore the company’s effective business strategy and operational efficiency.

Entero’s organic growth rate of 18 percent continues to surpass the broader pharmaceutical market, highlighting its competitive edge. Management remains optimistic about sustaining this momentum, citing multiple growth drivers within the business. The 140 basis points year-on-year improvement in EBITDA margin was supported by disciplined cost control measures and increased contribution from the MedTech segment.

Following a solid first half of FY27, Entero’s leadership expects to exceed its full-year revenue growth forecast of 23 percent. Industry analysts at ICICI Securities noted the company’s potential to generate over ₹200 crore in operating cash flow during FY27. This cash could be used to fuel expansion through mergers and acquisitions or by increasing stakes in partially owned subsidiaries. ICICI Securities has maintained a 'BUY' rating on Entero Healthcare stock, setting a target price of ₹2,100 based on a 17 times EV/EBITDA multiple for FY28 estimates.

Entero has been steadily reinforcing its position in the healthcare distribution sector. Its organic growth, around 20 percent, remains ahead of industry averages. The company’s ability to diversify its product range and increase sales from existing customers has contributed to consistent growth between 17 and 20 percent over the last four quarters. This expansion aligns with broader trends in healthcare, where companies that can offer a varied portfolio and solid distribution networks tend to perform well.

Analysts emphasize the growing importance of Entero’s MedTech business, which now accounts for over 15 percent of its consolidated revenue. The MedTech market is relatively fragmented, offering opportunities for consolidation and new product introductions. By deepening market penetration and forming partnerships with medical technology manufacturers, Entero could continue to enhance both revenue and profitability.

Looking ahead, Entero’s FY27 revenue growth guidance of 23 percent appears achievable, driven by organic expansion and the calendar impact of recent acquisitions. Operating cash flow to EBITDA conversion is expected to be around 50 percent, reflecting efficient cash management. Notably, the company’s projections do not factor in any new acquisitions, which may provide additional growth potential.

Management anticipates that over the next three years, Entero will maintain revenue growth above 20 percent, primarily through organic channels, while improving EBITDA margins beyond 6 percent. The company also expects that changes in hospital pricing and oncology product pricing will have limited effects on its margin profile.

Entero Healthcare remains focused on combining steady organic growth with selective acquisitions that add value without compromising margins. Its financial health is improving, supported by reduced working capital requirements as the business scales. Analysts from Jefferies have revised their earnings per share estimates upward by 3 to 8 percent for FY27 to FY29, reflecting the company’s solid growth and margin trends. Jefferies continues to recommend buying the stock, with a price target of ₹2,100 based on 28 times projected December 2028 earnings.

This positive outlook highlights Entero Healthcare’s strategic positioning within the pharmaceutical and medical distribution market. As demand for healthcare products and services expands, companies like Entero that emphasize innovation, efficient distribution, and financial discipline are well placed to benefit.

Disclaimer: The views and forecasts presented come from brokerage firms and analysts cited in this report. They do not necessarily represent the opinions of Business Standard. Readers should exercise their own judgment when making investment decisions.